| Q90264256 | A Multicenter, International Cohort Analysis of 1435 Cases to Support Clinical Trial Design in Acute Pancreatitis |
| Q47911499 | A Study on the Activation Peptide Released from Procarboxypeptidase B (CAPAP) and Anionic Trypsinogen in Patients with Acute Abdominal Disorders of Non-Pancreatic Origin |
| Q36844393 | A comparison of the BISAP score and serum procalcitonin for predicting the severity of acute pancreatitis |
| Q40642626 | ACE inhibition and cardiovascular mortality and morbidity in essential hypertension: the end of the search or a need for further investigations? |
| Q73432099 | ALLHAT: a saga of missed opportunities |
| Q35083871 | Acute biliary pancreatitis, endoscopy, and laparoscopy |
| Q33738066 | Acute biliary pancreatitis: diagnosis and treatment |
| Q83289569 | Acute pancreatitis |
| Q43088026 | Acute pancreatitis at the beginning of the 21st century: the state of the art. |
| Q46143168 | Acute pancreatitis in Soweto, South Africa: relationship between trypsinogen load, trypsinogen activation, and fibrinolysis |
| Q42084167 | Acute pancreatitis--from cellular signalling to complicated clinical course. |
| Q35607793 | Acute pancreatitis: molecular biology update |
| Q46243740 | Applying Ockham's razor to pancreatitis prognostication: a four-variable predictive model |
| Q37224469 | Are hypertensive elderly patients treated differently? |
| Q44317694 | Assessing the severity of canine pancreatitis. |
| Q82041583 | Association between remote organ injury and tissue polyamine homeostasis in acute experimental pancreatitis - treatment with a polyamine analogue bismethylspermine |
| Q35769864 | Biochemical markers of acute pancreatitis. |
| Q35124979 | Blood Pressure and Lipid Lowering in the Prevention of Stroke: A Note to Neurologists |
| Q52860663 | Calcitonin precursors in the prediction of severity of acute pancreatitis on the day of admission. |
| Q34087669 | Calcium signaling and acute pancreatitis: specific response to a promiscuous messenger |
| Q37284059 | Calcium-dependent enzyme activation and vacuole formation in the apical granular region of pancreatic acinar cells |
| Q41862502 | Cathepsin B Activity Initiates Apoptosis via Digestive Protease Activation in Pancreatic Acinar Cells and Experimental Pancreatitis. |
| Q42273053 | Cathepsin L inactivates human trypsinogen, whereas cathepsin L-deletion reduces the severity of pancreatitis in mice. |
| Q38542886 | Circulating nucleosomes as predictive markers of severe acute pancreatitis. |
| Q30431045 | Clinical and pathologic characteristics of pancreatic necrosis in critically ill children. |
| Q73655767 | Clinical value of lipopolysaccharide-binding protein (LBP) determinations in acute pancreatitis |
| Q36497068 | Clinical value of rapid urine trypsinogen-2 test strip, urinary trypsinogen activation peptide, and serum and urinary activation peptide of carboxypeptidase B in acute pancreatitis |
| Q42020381 | Comparison of APACHE II and Imrie Scoring Systems in predicting the severity of Acute Pancreatitis |
| Q41963140 | Comparison of Ranson, Glasgow, MOSS, SIRS, BISAP, APACHE-II, CTSI Scores, IL-6, CRP, and Procalcitonin in Predicting Severity, Organ Failure, Pancreatic Necrosis, and Mortality in Acute Pancreatitis |
| Q35128186 | Comparison of scoring systems in predicting the severity of acute pancreatitis |
| Q44770298 | Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20 mg vs losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients |
| Q37221500 | Criteria for the diagnosis and severity stratification of acute pancreatitis |
| Q36062888 | Current management of acute pancreatitis |
| Q81350333 | Current management of acute pancreatitis |
| Q44781606 | Cytokine release, pancreatic injury, and risk of acute pancreatitis after spinal fusion surgery |
| Q24792999 | Debate: does it matter how you lower blood pressure? |
| Q26739913 | Defining post-operative pancreatitis as a new pancreatic specific complication following pancreatic resection |
| Q61812668 | Early Warning Scores Predict Outcome in Acute Pancreatitis |
| Q55043783 | Early assessment of pancreatic infections and overall prognosis in severe acute pancreatitis by procalcitonin (PCT): a prospective international multicenter study. |
| Q40846144 | Early biliary decompression versus conservative treatment in acute biliary pancreatitis (APEC trial): study protocol for a randomized controlled trial |
| Q34225228 | Early diagnosis and prediction of severity in acute pancreatitis using the urine trypsinogen-2 dipstick test: a prospective study |
| Q50211734 | Early diagnosis of pancreatic necrosis based on perfusion CT to predict the severity of acute pancreatitis. |
| Q88846794 | Early differential diagnosis of the severity of acute pancreatitis |
| Q34156774 | Early organ dysfunction affects long-term survival in acute pancreatitis patients |
| Q73911990 | Efficacy, safety and cost of new cardiovascular drugs: a survey |
| Q31151502 | Endothelin(A) receptor blockade reduces ischemia/reperfusion injury in pig pancreas transplantation |
| Q33654180 | Expression of human cationic trypsinogen (PRSS1) in murine acinar cells promotes pancreatitis and apoptotic cell death |
| Q36474514 | Hemoconcentration is a poor predictor of severity in acute pancreatitis |
| Q46781630 | Incidence, risk factors and clinical course of pancreatic fluid collections in acute pancreatitis |
| Q54664671 | Is the monocyte chemotactic protein-1 -2518 G allele a risk factor for severe acute pancreatitis? |
| Q37425925 | JPN Guidelines for the management of acute pancreatitis: severity assessment of acute pancreatitis |
| Q85034531 | Magnetic resonance imaging versus Acute Physiology And Chronic Healthy Evaluation II score in predicting the severity of acute pancreatitis |
| Q34512097 | Management of necrotizing pancreatitis |
| Q37037412 | Mechanism of mitochondrial permeability transition pore induction and damage in the pancreas: inhibition prevents acute pancreatitis by protecting production of ATP. |
| Q35821157 | Pancreatic Perfusion CT in Early Stage of Severe Acute Pancreatitis |
| Q35119700 | Pancreatitis. |
| Q53521007 | Plasma calprotectin levels in patients suffering from acute pancreatitis. |
| Q79763235 | Potential of adipocytokines in predicting peripancreatic necrosis and severity in acute pancreatitis: pilot study |
| Q36785154 | Predicting severity of acute pancreatitis |
| Q34882213 | Prediction of the severity of acute pancreatitis on admission by urinary trypsinogen activation peptide: a meta-analysis |
| Q37649334 | Predictive factors for severe evolution in acute pancreatitis and a new score for predicting a severe outcome |
| Q79299181 | Predictive value of complement activation fragments C3a and sC5b‐9 for development of severe disease in patients with acute pancreatitis |
| Q38087919 | Predictors of adverse outcomes in acute pancreatitis: new horizons |
| Q34765099 | Prognosis in acute pancreatitis |
| Q43588560 | Prognostic factors for acute pancreatitis |
| Q44874967 | Proteinuria and urinary beta 2-microglobulin as markers of tubular malfunction in the assessment of severity of acute pancreatitis |
| Q44417540 | Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine |
| Q26783422 | Role of Biomarkers in Diagnosis and Prognostic Evaluation of Acute Pancreatitis |
| Q38107378 | Scoring of human acute pancreatitis: state of the art. |
| Q29994579 | Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis |
| Q35594879 | Serum levels of procarboxypeptidase B and its activation peptide in patients with acute pancreatitis and non-pancreatic diseases |
| Q37060412 | Severe acute pancreatitis: pathogenetic aspects and prognostic factors |
| Q37172829 | Soluble E-cadherin: an early marker of severity in acute pancreatitis. |
| Q79074500 | The ALLHAT study: results and clinical implications |
| Q33725992 | The Association of Computed Tomography-Assessed Body Composition with Mortality in Patients with Necrotizing Pancreatitis |
| Q35587336 | The Use of Calcium Antagonists in the Therapy of Hypertension in the Elderly |
| Q88898588 | The ability of emergency physicians to diagnose and score acute pancreatitis on computed tomography |
| Q38198861 | Treatment options for acute pancreatitis |
| Q73208462 | Trypsinogen activation peptide in acute pancreatitis |
| Q73634230 | Trypsinogen-2 and trypsinogen activation peptide (TAP) in urine of patients with acute pancreatitis |
| Q43004260 | UK guidelines for management of acute pancreatitis: is it time to change? |
| Q24685861 | UK guidelines for the management of acute pancreatitis |
| Q74637126 | Urinary trypsinogen activation peptide is more accurate than hematocrit in determining severity in patients with acute pancreatitis: a prospective study |
| Q35128138 | Useful Markers for Predicting Severity and Monitoring Progression of Acute Pancreatitis |
| Q60920095 | Usefulness of urinary trypsinogen-2 and trypsinogen activation peptide in acute pancreatitis: A multicenter study in Japan |
| Q55709326 | Utility of serum phosphate as a marker for predicting the severity of post-endoscopic retrograde cholangiopancreatography pancreatitis. |
| Q42265681 | What is New in Acute Pancreatitis? |
| Q72997002 | [Modulation of immune response in severe acute pancreatitis. Present and future view] |
| Q78688597 | [Those who read medical articles are at risk of dying due to a typing error] |